Bloomberg Intelligence Novo Next-Generation Obesity Shot Falls Short of Lilly Rival
10 snips
Feb 23, 2026 Holly Froum, litigation analyst who breaks down tariff legality and refund procedures. Mary Ross Gilbert, senior retail analyst focused on apparel margins and sourcing shifts. Sam Fazelli, senior pharma analyst specializing in drug pipelines and industry strategy. They discuss Novo Nordisk's next-gen obesity shot underperforming versus Lilly, scientific choices behind the outcomes, and how tariff rulings reshape retailer margins and sourcing.
AI Snips
Chapters
Transcript
Episode notes
Novo's Next-Gen Shot Comes Up Short
- Novo Nordisk's next-gen obesity shot Cagri Sema delivered 20.2% weight loss at 84 weeks versus Eli Lilly's 23.6%, causing market perception that Novo fell behind.
- Sam Fazeli says the head-to-head trial was designed to show noninferiority and it failed, giving Eli Lilly an easy marketing advantage.
Small Percentage Gaps Drive Big Commercial Outcomes
- Weight-loss percentage differences matter commercially even if clinically many patients succeed; Lilly can market superiority and scale supply accordingly.
- Fazeli warns that headline percent weight loss drives prescribing and sales more than subtler measures like muscle or visceral fat outcomes.
Different Biological Bets Explain Market Shift
- The divergence reflects different scientific bets: Eli Lilly combined GLP-1 with GIP and hit a high-performance formula while Novo focused on amylin combinations.
- Fazeli frames Lilly's success as either luck or a contrarian biologist finding the right mechanism, explaining why Novo's route underperformed.